All Stories

  1. Ataxin-2 in the hypothalamus at the crossroads between metabolism and clock genes
  2. The impact of insomnia on frailty and the hallmarks of aging
  3. SIRT1 activation and its circadian clock control: a promising approach against (frailty in) neurodegenerative disorders
  4. Peripheral biomarkers to diagnose obstructive sleep apnea in adults: A systematic review and meta-analysis
  5. SIRT2 Deficiency Exacerbates Hepatic Steatosis via a Putative Role of the ER Stress Pathway
  6. PET Imaging of the Neuropeptide Y System: A Systematic Review
  7. A look on food intake and satiety: from humans to rodent models
  8. Skin senescence: mechanisms and impact on whole-body aging
  9. Blueberry Counteracts Prediabetes in a Hypercaloric Diet-Induced Rat Model and Rescues Hepatic Mitochondrial Bioenergetics
  10. Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases
  11. PI3K/AKT/MTOR and ERK1/2-MAPK signaling pathways are involved in autophagy stimulation induced by caloric restriction or caloric restriction mimetics in cortical neurons
  12. Long-term continuous positive airway pressure treatment ameliorates biological clock disruptions in obstructive sleep apnea
  13. Neuropeptide Y (NPY) intranasal delivery alleviates Machado–Joseph disease
  14. Common risk factors and therapeutic targets in obstructive sleep apnea and osteoarthritis: An unexpectable link?
  15. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  16. The Superpowers of Our Sleep
  17. Blueberry Consumption Challenges Hepatic Mitochondrial Bioenergetics and Elicits Transcriptomics Reprogramming in Healthy Wistar Rats
  18. Trehalose alleviates the phenotype of Machado–Joseph disease mouse models
  19. Neuropeptide Y Enhances Progerin Clearance and Ameliorates the Senescent Phenotype of Human Hutchinson-Gilford Progeria Syndrome Cells
  20. Long-Term Continuous Positive Airway Pressure Treatment Ameliorates Biological Clock Disruptions in Obstructive Sleep Apnea
  21. Dichotomous Sirtuins: Implications for Drug Discovery in Neurodegenerative and Cardiometabolic Diseases
  22. The importance of determining circadian parameters in pharmacological studies
  23. In vitro susceptibility of Trypanosoma brucei brucei to selected essential oils and their major components
  24. Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice
  25. Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis
  26. Role of Beta-adrenergic Receptors and Sirtuin Signaling in the Heart During Aging, Heart Failure, and Adaptation to Stress
  27. Obstructive Sleep Apnea and Hallmarks of Aging
  28. The NAD+-dependent deacetylase SIRT2 attenuates oxidative stress and mitochondrial dysfunction and improves insulin sensitivity in hepatocytes
  29. Quizzes as an active learning strategy: A study with students of pharmaceutical sciences
  30. Unraveling the Role of Ataxin-2 in Metabolism
  31. Hypoxia mimetic induces lipid accumulation through mitochondrial dysfunction and stimulates autophagy in murine preadipocyte cell line
  32. Hypothalamic Dysfunction in Obesity and Metabolic Disorders
  33. Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases
  34. Caloric restriction stimulates autophagy in rat cortical neurons through neuropeptide Y and ghrelin receptors activation
  35. The pathophysiology of defective proteostasis in the hypothalamus — from obesity to ageing
  36. Antileishmanial activity of antiretroviral drugs combined with miltefosine
  37. Corrigendum to “Intracellular mechanisms coupled to NPY Y2 and Y5 receptor activation and lipid accumulation in murine adipocytes” [neuropeptides 46/6 (2012) 359–366]
  38. Caloric restriction blocks neuropathology and motor deficits in Machado–Joseph disease mouse models through SIRT1 pathway
  39. The Adenosinergic System in Diabetic Retinopathy
  40. Neuropeptide Y: An Anti-Aging Player?
  41. Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism
  42. Impaired adrenal medullary function in a mouse model of depression induced by unpredictable chronic stress
  43. Activation of Neuropeptide Y Receptors Modulates Retinal Ganglion Cell Physiology and Exerts Neuroprotective ActionsIn Vitro
  44. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado–Joseph disease
  45. Neuropeptide Y system in the retina: From localization to function
  46. NPY/neuropeptide Y enhances autophagy in the hypothalamus: a mechanism to delay aging?
  47. Neuropeptide Y stimulates autophagy in hypothalamic neurons
  48. Hypothalamic involvement in premature aging laminopathies
  49. Alterations in phospholipidomic profile in the brain of mouse model of depression induced by chronic unpredictable stress
  50. Fluoxetine Induces Proliferation and Inhibits Differentiation of Hypothalamic Neuroprogenitor Cells In Vitro
  51. Role of hypothalamic neurogenesis in feeding regulation
  52. MicroRNAs in Obesity and Metabolism
  53. Catecholamine Release Modulation by Adenosine through A2AReceptors in Mouse Chromaffin Cell Culture
  54. Chronic Unpredictable Stress Induces Catecholaminergic System Changes in Mouse Adrenal Gland
  55. Emerging novel roles of neuropeptide Y in the retina: From neuromodulation to neuroprotection
  56. Progenitor Cells in Chromospheres: In Response to Arthur S. Tischler
  57. Effect of Diabetes/Hyperglycemia on the Rat Retinal Adenosinergic System
  58. Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate
  59. Neuropeptide Y Receptors Y 1 and Y 2 are Present in Neurons and Glial Cells in Rat Retinal Cells in Culture
  60. Intracellular mechanisms coupled to NPY Y2 and Y5 receptor activation and lipid accumulation in murine adipocytes
  61. Isolation, Characterization, and Differentiation of Progenitor Cells from Human Adult Adrenal Medulla
  62. Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression
  63. Contribution of TNF receptor 1 to retinal neural cell death induced by elevated glucose
  64. Regulation of catecholamine release in human adrenal chromaffin cells by β-adrenoceptors
  65. Effects of 3,4-Methylenedioxymethamphetamine Administration on Retinal Physiology in the Rat
  66. Moderate Long-Term Modulation of Neuropeptide Y in Hypothalamic Arcuate Nucleus Induces Energy Balance Alterations in Adult Rats
  67. Proliferative Hypothalamic Neurospheres Express NPY, AGRP, POMC, CART and Orexin-A and Differentiate to Functional Neurons
  68. Neuropeptide Y inhibits [Ca2+]ichanges in rat retinal neurons through NPY Y1, Y4, and Y5receptors
  69. Regulation of catecholamine release and tyrosine hydroxylase in human adrenal chromaffin cells by interleukin-1β: role of neuropeptide Y and nitric oxide
  70. Neuropeptide Y Family Peptides
  71. Stress-Induced Hypertension and Increased Sympathetic Activity in Mice Overexpressing Neuropeptide Y in Noradrenergic Neurons
  72. Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia
  73. Neuropeptide Y stimulates retinal neural cell proliferation - involvement of nitric oxide
  74. Neuropeptide Y protects retinal neural cells against cell death induced by ecstasy
  75. Intracellular signaling mechanisms mediating catecholamine release upon activation of NPY Y1receptors in mouse chromaffin cells
  76. NPY in rat retina is present in neurons, in endothelial cells and also in microglial and Müller cells
  77. NPY Y1 receptor is not involved in the hemodynamic response to an acute cold pressor test in mice
  78. Neuropeptide Y regulates catecholamine release evoked by interleukin-1β in mouse chromaffin cells
  79. Deletion of the neuropeptide Y (NPY) Y 1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion
  80. The Putative Neuroprotective Role of Neuropeptide Y in the Central Nervous System
  81. Neuropeptide Y expression, localization and cellular transducing effects in HUVEC
  82. Up-regulation of neuropeptide Y levels and modulation of glutamate release through neuropeptide Y receptors in the hippocampus of kainate-induced epileptic rats
  83. NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-α and IFN-γ in HUVEC
  84. Blood sampling methodology is crucial for precise measurement of plasma catecholamines concentrations in mice
  85. Angiotensin II mediates catecholamine and neuropeptide Y secretion in human adrenal chromaffin cells through the AT1 receptor
  86. Neuropeptide Y and its receptors as potential therapeutic drug targets
  87. Catecholamine and Neuropeptide Y Secretion from Human Adrenal Chromaffin Cells
  88. Differential Secretion of Catecholamine and Neuropeptide Y in Response to KCl from Mice Chromaffin Cells
  89. Dibasic cleavage site is required for sorting to the regulated secretory pathway for both pro- and neuropeptide Y
  90. Interplay Between Galanin and Leptin in the Hypothalamic Control of Feeding via Corticotropin-Releasing Hormone and Neuropeptide Y
  91. Cardiovascular effects of fentanyl in conscious rats
  92. In vitro study of the interaction of Tilia europeae L. aqueous extract with GABAA receptors in rat brain